Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) last night announced the launch of RAJANI in the US. RAJANI is the generic equivalent of Beyaz, an oral contraceptive, available in a 28-day blister pack dispenser for use by women, which has annual sales of $133 million in the US.
RAJANI: prevents pregnancy; treats symptoms of premenstrual dysphoric disorder (PMDD) in women choosing to use an oral contraceptive for contraception; treats moderate acne for women at least 14 years old if the patient desires an oral contraceptive for birth control; and raises folate levels in women who choose to use an oral contraceptive for contraception. It does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. This product enhances Teva’s already comprehensive oral contraceptive portfolio. Teva has over 300 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. One in six generic prescriptions dispensed in the US is filled with a Teva generic product.
Published by Globes [online], Israel business news - www.globes-online.com - on October 13, 2016
© Copyright of Globes Publisher Itonut (1983) Ltd. 2016